Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

作者: Chang-Qi Zhu , Gilda da Cunha Santos , Keyue Ding , Akira Sakurada , Jean-Claude Cutz

DOI: 10.1200/JCO.2007.14.8924

关键词: Epidermal growth factor receptorErlotinibKRASMedicineCancer researchSurvival analysisTyrosine-kinase inhibitorCancerCarcinomaErlotinib HydrochlorideOncology

摘要: PurposeTo evaluate the effect of KRAS and epidermal growth factor receptor (EGFR) genotype on the response to erlotinib treatment in the BR.21, placebo-controlled trial.Patients and MethodsWe analyzed 206 tumors for KRAS mutation, 204 tumors for EGFR mutation, and 159 tumors for EGFR gene copy by fluorescent in situ hybridization (FISH). We reanalyzed EGFR deletion/mutation using two highly sensitive techniques that detect abnormalities in samples with 5% to 10% tumor cellularity. KRAS mutation was analyzed by direct sequencing.ResultsThirty patients (15%) had KRAS mutations, 34 (17%) had EGFR exon 19 deletion or exon 21 L858R mutations, and 61 (38%) had high EGFR gene copy (FISH positive). Response rates were 10% for wild-type and 5% for mutant KRAS (P = .69), 7% for wild-type and 27% for mutant EGFR (P = .03), and 5% for EGFR FISH-negative and 21% for FISH-positive patients (P = .02). Significant survival benefit from erlotinib therapy was observed for patients with wild-type KRAS (hazard ratio [HR] = 0.69, P = .03) and EGFR FISH positivity (HR = 0.43, P = .004) but not for patients with mutant KRAS (HR = 1.67, P = .31), wild-type EGFR (HR = 0.74, P = .09), mutant EGFR (HR = 0.55, P = .12), and EGFR FISH negativity (HR = 0.80, P = .35). In multivariate analysis, only EGFR FISH-positive status was prognostic for poorer survival (P = .025) and predictive of differential survival benefit from erlotinib (P = .005).ConclusionEGFR mutations and high copy number are predictive of response to erlotinib. EGFR FISH is the strongest prognostic marker and a significant predictive marker of differential survival benefit from erlotinib.

参考文章(26)
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Qiulu Pan, William Pao, Marc Ladanyi, Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas The Journal of Molecular Diagnostics. ,vol. 7, pp. 396- 403 ,(2005) , 10.1016/S1525-1578(10)60569-7
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi, Stefania Bartolini, Giovanni L. Ceresoli, Lynne Bemis, Jerry Haney, Samir Witta, Kathleen Danenberg, Irene Domenichini, Vienna Ludovini, Elisabetta Magrini, Vanesa Gregorc, Claudio Doglioni, Angelo Sidoni, Maurizio Tonato, Wilbur A. Franklin, Lucio Crino, Paul A. Bunn, Marileila Varella-Garcia, Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 97, pp. 643- 655 ,(2005) , 10.1093/JNCI/DJI112
Sarit Aviel-Ronen, Fiona H. Blackhall, Frances A. Shepherd, Ming-Sound Tsao, K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review Clinical Lung Cancer. ,vol. 8, pp. 30- 38 ,(2006) , 10.3816/CLC.2006.N.030
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Hideharu Kimura, Yutaka Fujiwara, Takashi Sone, Hideo Kunitoh, Tomohide Tamura, Kazuo Kasahara, Kazuto Nishio, High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients Cancer Science. ,vol. 97, pp. 642- 648 ,(2006) , 10.1111/J.1349-7006.2006.00216.X
Jean-Yves Douillard, Edward Kim, Vera Hirsh, Tony Mok, Mark Socinski, Radj Gervais, Yi-Long Wu, Longyun Li, Mark Sellers, Elizabeth Lowe, PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST) Journal of Thoracic Oncology. ,vol. 2, pp. S305- S306 ,(2007) , 10.1097/01.JTO.0000283087.71346.19
A-P. Meert, B. Martin, P. Delmotte, T. Berghmans, J-J. Lafitte, C. Mascaux, M. Paesmans, E. Steels, J-M. Verdebout, J-P. Sculier, The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis European Respiratory Journal. ,vol. 20, pp. 975- 981 ,(2002) , 10.1183/09031936.02.00296502
Issan Yee San Tam, Lap Ping Chung, Wai Sing Suen, Elaine Wang, May C.M. Wong, Kok Keung Ho, Wah Kit Lam, Shui Wah Chiu, Luc Girard, John D. Minna, Adi F. Gazdar, Maria P. Wong, Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clinical Cancer Research. ,vol. 12, pp. 1647- 1653 ,(2006) , 10.1158/1078-0432.CCR-05-1981